Biogen Inc. joined a consortium to build a collection of biological and medical data, where the company’s employees who had tested for and recovered from the coronavirus would be able to participate.
Swiss company Vifor Pharma and Germany’s Evotec AG launched a joint venture to focus on the discovery and development of new therapies for kidney diseases.
Before there are new therapies to set a firm apart, there is a far more fundamental need that competitiveness will ultimately hinge on: high-quality, diversified, annotated human biospecimens.
